



Malmö 14 December 2022

**PRESS RELEASE**

### **First subjects dosed in Aptahem's FIH study**

**Aptahem AB (publ), a biotech company developing treatments for patients suffering from acute inflammatory diseases such as sepsis, announces today that the first healthy volunteers (HV) have been dosed in the clinical First in Human (FIH) study.**

The first HV subjects have now successfully been dosed in the randomized, placebo-controlled Phase 1 study which will evaluate the safety and tolerability of intravenous Apta-1 in healthy volunteers.

#### **For further information:**

Aptahem AB

Mikael Lindstam, CEO

Tel: +46 (0)766-33 36 99

E-mail: [ml@aptahem.com](mailto:ml@aptahem.com)

#### **About Aptahem**

Aptahem AB (APTA) is a clinical stage biotechnology company that develops aptamer-based pharmaceuticals for the treatment of acute, life-threatening conditions in which a combination of coagulation, inflammation and tissue damage are involved. The company's lead candidate, Apta-1, is currently in early clinical phase. Apta-1 has in preclinical studies, by its anti-thrombotic, immunomodulating and tissue repairing characteristics, shown very positive and promising results as treatment for sepsis and critical conditions associated with sepsis. For more information, please visit [www.aptahem.com](http://www.aptahem.com)